SEC Form 4 · accession 0000904454-18-000646
Paratek Pharmaceuticals, Inc. · PRTK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Adam Woodrow
Officer — VP & Chief Commercial Officer
Period of report
Oct 2, 2018
Accepted (ET)
Oct 4, 2018 · 9:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178711
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 2, 2018 | A | 23,750 | $0.00 | A | 112,917 | D | |
| Common StockF2 | Oct 2, 2018 | A | 27,500 | $0.00 | A | 140,417 | D | |
| Common StockF3,F4 | Oct 3, 2018 | S | 8,750 | $9.82 | D | 131,667 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents performance-based restricted stock units ("PRSUs") granted on February 2, 2017 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on October 2, 2018.
- F2Represents PRSUs granted on August 3, 2017 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on October 2, 2018. These PRSUs will settle in shares of common stock on October 2, 2019, provided that the Reporting Person remains in continuous service with Paratek Pharmaceuticals, Inc. through the settlement date.
- F3Sale of shares to cover personal income tax obligations upon vesting of PRSUs, pursuant to Rule 10b5-1 trading plan.
- F4The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.75 to $9.95. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 to this Form 4.